<DOC>
	<DOCNO>NCT01014078</DOCNO>
	<brief_summary>The objective study compare safety efficacy azithromycin ophthalmic solution , 1 % dry eye subject four week treatment period , use placebo comparison .</brief_summary>
	<brief_title>A Four Week Study Azithromycin Ophthalmic Solution , 1 % Versus Placebo Subjects With Dry Eye Disease</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Azithromycin</mesh_term>
	<criteria>Have current diagnosis dry eye one eye Moderate severe degree meibomian gland plug Have best correct visual acuity eye least +0.7 LogMAR If female , nonpregnant nonlactating Have anterior blepharitis Have lid structural abnormality Have suspect ocular fungal viral infection Have penetrate intraocular surgery past 90 day require penetrate intraocular surgery study Have ocular surface surgery [ e.g. , laserassisted situ keratomileusis ( LASIK ) , refractive , pterygium ] within past year . Unable withhold use contact lens study Have know hypersensitivity azithromycin , erythromycin , macrolide antibiotic , ingredient study medication . Have history post vitreous detachment . Are consider legally blind 1 eye ( LogMAR BCVA= 1.0 Snellen BCVA= 20/200 ) . Have permanent conjunctival goblet cell loss scar condition , include cicatricial blepharitis conjunctivitis . Have congenitally absent meibomian gland lacrimal gland . Have cauterization punctum punctal plug ( silicone collagen ) insert remove within 90 day prior screen . Have serious medical condition would confound study assessment . Have concomitant ocular pathology , opinion investigator , may confound study assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>